High platelet reactivity - the challenge of prolonged anticoagulation therapy after ACS

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 799-807

  Brouwer, Marc A ^a   Focks, Jeroen Jaspers ^a   Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Coagulation inhibitors; Coronary syndrome; Direct antithrombin agents; Heparins; Oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; CREATININE; DABIGATRAN; DAREXABAN; ENOXAPARIN; FIBRINOGEN RECEPTOR; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; PRASUGREL; PROTAMINE; PROTHROMBIN; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; TICAGRELOR; TICLOPIDINE; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION; RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877034337     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-08-0582     Document Type: Article

References (59)

1. AntiThrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849-1860.
2. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
4. Wallentin L, Becker RC, Bidai A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
5. Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularisation. N Engl J Med 2012; 367: 1297-1309.
6. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
7. Steg G, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619.
8. Palmerini T, Dangas G, Mehran R, et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ Cardiovasc Interv 2011; 4: 577-584.
9. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
10. Dangas GD, Claessen BE, Mehran R, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: Results from the HORIZONS- AMI (Harmonizing Outcomes with Revascularisation and Stents in Acute Myocardial Infarction) Trial. JACC 2012; 59: 1752-1759.
11. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
12. Sibbing D, Byrne RA, Bernlochner I, et al. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202.
13. Collet JP, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
14. Furie B, Furie BC. Mechanism of thrombus formation. N Engl J Med 2008; 359: 938-949.
15. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. J Am Med Assoc 1996; 276: 811-815.
16. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes, a systematic overview. J Am Med Assoc 2004; 292: 89-96.
17. De Luca G, Marino P. Adjunctive benefits from low-molecular weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007; 154: 1085.e1-6.
18. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
19. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1930.
20. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
21. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
22. Brouwer MA, Verheugt FWA. Oral anticoagulation for acute coronary syndromes. Circulation 2002; 105: 1270-1274.
23. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and lowdose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437.
24. Williams MJA, Morison IM, Parker JH, et al. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30: 364-369.
25. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 trial. Circulation 2002; 106: 659-665.
26. Brouwer MA, Clappers N, Verheugt FWA. Adjunctive treatment in patients treated with thrombolytic therapy. Heart 2004; 90: 581-588.
27. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HART II). Circulation 2001; 104: 648-652.
28. Wijns W, Kohl P, Danchin N, et al. Guidelines on myocardial revascularisation: the Task Force on myocardial revascularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
29. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-1863.
30. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 789-797.
31. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med 2011; 365: 883-891.
32. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with AF. N Engl J Med 2011; 365: 981-992.
33. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
34. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
35. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, doubleblind, phase II trial. Eur Heart J 2011; 32: 2781-2789.
36. Andreotti F, Testa L, Biondi-Zoccai GGL, et al. Aspirin plus warfarin compared to aspirin alone after coronary syndromes: an updated and comprehensive meta-analysis of 25. 307 patients. Eur Heart J 2006; 27: 519-526.
37. ten Berg JM, Kelder JC, Suttorp MJ, et al. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000; 102: 386-391.
38. Testa L, Zoccai GB, Porto I, et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007; 99: 1637-1642.
39. van Geest-Daalderop JHH, Hutten BA, Sturk A, et al. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J Thromb Thrombolysis 2003; 15: 197-203.
40. Cosmi B, Rubboli A, Castelvetri C, et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001; 4: CD002133.
41. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
42. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-2353.
43. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non- ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009; 119: 1873-1882.
44. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
45. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
46. de Araujo Goncalves P, Ferreira J, Aguiar C, et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularisation in NSTE-ACS. Eur Heart J 2005; 26: 865-872.
47. Flather MD, Weitz JI, Yusuf S, et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. Eur Heart J 2000; 21: 1473-1481.
48. Testa L, Zoccai GB, Porto I, et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007; 99: 1637-1642.
49. De Wilde W, Oirbans T, Verheugt F, et al. Use of clopidogrel with or without aspirin and undergoing percutaneous coronary intervention: an open-label randomised, controlled trial. Lancet 2013; epub ahead of print.
50. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischaemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
51. Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, doubleblind, phase II trial. Lancet 2009; 374: 29-38.
52. Steg G, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo- controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32: 2541-2554.
53. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients with ST-elevation myocardial infarction: Results from ATLAS ACS 2-TIMI 51. Presented at the European Society of Cardiology Annual Congress, Munich, Germany, August 25-29, 2012; Abstract session 710007-710008.
54. Lamberts M, Olesen JB, Ruwald MH, et al Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in AF patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; epub ahead of print.
55. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
56. Gao F, Zhou YJ, Wang ZJ, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol 2010; 148: 96-101.
57. De Wilde W, ten Berg J, et al. Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J 2009; 158: 713-718.
58. Lip GYH, Huber K, Andreotti F, et al. Management of antithrombotic therapy in AF patients presenting with acute coronary syndrome and/or undergoing percutaneous intervention/stenting. A consensus document of the European Society of Cardiology working group on thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010; 103: 13-28.
59. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.